SM
REVBW icon

Skaana Management’s Revelation Biosciences Warrant REVBW Stock Holding History

Skaana Management’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,815
Closed -$2K – 125
2022
Q1 		$2K Hold
17,815
– – ﹤0.01% 123
2021
Q4 		$12K Buy
+17,815
New +$10.9K ﹤0.01% 174

Other funds holding REVBW

OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Skaana Management's REVBW Position: Q2 2022 in Review

Skaana Management sold out of Revelation Biosciences Warrant (REVBW) in Q2 2022, closing a stake of 17,815 shares — an estimated $2K sold.

Skaana Management first reported a position in REVBW in Q4 2021 and held it in 2 quarters. The position peaked at $12K in Q4 2021. 17 funds tracked by Wall St. Rank hold REVBW as of Q2 2022.

  • Skaana Management reported no remaining Revelation Biosciences Warrant position as of Q2 2022 after selling out during the quarter.
  • Skaana Management sold 17,815 Revelation Biosciences Warrant shares in Q2 2022, an estimated $2K.
  • Skaana Management first reported a position in Revelation Biosciences Warrant in Q4 2021 and held it in 2 quarters.
  • Skaana Management's Revelation Biosciences Warrant position peaked at $12K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q2 2022.

Based on Skaana Management's 13F filing for Q2 2022, filed 11 Aug 2022.